Research ExplorerPublicationsClinical and pathological nodal staging score for urothelial...

Clinical and pathological nodal staging score for urothelial carcinoma of the bladder

Standard

Clinical and pathological nodal staging score for urothelial carcinoma of the bladder : an external validation. / Gierth, M; Fritsche, H M; Buchner, H; May, M; Aziz, A; Otto, W; Bolenz, C; Trojan, L; Hermann, E; Tiemann, A; Müller, S C; Ellinger, J; Brookman-May, S; Stief, C G; Tilki, D; Nuhn, P; Höfner, T; Hohenfellner, M; Haferkamp, A; Roigas, J; Zacharias, M; Wieland, W F; Riedmiller, H; Denzinger, S; Bastian, P J; Burger, M.

In: WORLD J UROL, Vol. 32, No. 2, 04.2014, p. 365-71.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Gierth, M, Fritsche, HM, Buchner, H, May, M, Aziz, A, Otto, W, Bolenz, C, Trojan, L, Hermann, E, Tiemann, A, Müller, SC, Ellinger, J, Brookman-May, S, Stief, CG, Tilki, D, Nuhn, P, Höfner, T, Hohenfellner, M, Haferkamp, A, Roigas, J, Zacharias, M, Wieland, WF, Riedmiller, H, Denzinger, S, Bastian, PJ & Burger, M 2014, 'Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation', WORLD J UROL, vol. 32, no. 2, pp. 365-71. https://doi.org/10.1007/s00345-013-1105-4

APA

Gierth, M., Fritsche, H. M., Buchner, H., May, M., Aziz, A., Otto, W., Bolenz, C., Trojan, L., Hermann, E., Tiemann, A., Müller, S. C., Ellinger, J., Brookman-May, S., Stief, C. G., Tilki, D., Nuhn, P., Höfner, T., Hohenfellner, M., Haferkamp, A., ... Burger, M. (2014). Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation. WORLD J UROL, 32(2), 365-71. https://doi.org/10.1007/s00345-013-1105-4

Vancouver

Gierth M, Fritsche HM, Buchner H, May M, Aziz A, Otto W et al. Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation. WORLD J UROL. 2014 Apr;32(2):365-71. https://doi.org/10.1007/s00345-013-1105-4

Bibtex

@article{f3db9ee6f623440a99b6eee4bf1df0b7,
title = "Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation",
abstract = "PURPOSE: Radical cystectomy (RC) and pelvic lymph node dissection (LND) are standard treatments for muscle-invasive urothelial carcinoma of the bladder. Lymph node staging is a prerequisite for clinical decision-making regarding adjuvant chemotherapy and follow-up regimens. Recently, the clinical and pathological nodal staging scores (cNSS and pNSS) were developed. Prior to RC, cNSS determines the minimum number of lymph nodes required to be dissected; pNSS quantifies the accuracy of negative nodal staging based on pT stage and dissected LNs. cNSS and pNSS have not been externally validated, and their relevance for prediction of cancer-specific mortality (CSM) has not been assessed.METHODS: In this retrospective study of 2,483 RC patients from eight German centers, we externally validated cNSS and pNSS and determined their prediction of CSM. All patients underwent RC and LND. Median follow-up was 44 months. cNSS and pNSS sensitivities were evaluated using the original beta-binominal models. Adjusted proportional hazards models were calculated for pN0 patients to assess the predictive value of cNSS and pNSS for CSM.RESULTS: cNSS and pNSS both pass external validation. Adjusted for other clinical parameters, cNSS can predict outcome after RC. pNSS has no independent impact on prediction of CSM. The retrospective design is the major limitation of the study.CONCLUSIONS: In the present external validation, we confirm the validity of both cNSS and pNSS. cNSS is an independent predictor of CSM, thus rendering it useful as a tool for planning the extent of LND.",
keywords = "Adult, Aged, Aged, 80 and over, Carcinoma, Transitional Cell, Chemotherapy, Adjuvant, Cohort Studies, Cystectomy, Disease-Free Survival, Female, Humans, Lymph Node Excision, Lymph Nodes, Male, Middle Aged, Neoplasm Staging, Pelvis, Proportional Hazards Models, Retrospective Studies, Treatment Outcome, Urinary Bladder Neoplasms, Journal Article, Validation Studies",
author = "M Gierth and Fritsche, {H M} and H Buchner and M May and A Aziz and W Otto and C Bolenz and L Trojan and E Hermann and A Tiemann and M{\"u}ller, {S C} and J Ellinger and S Brookman-May and Stief, {C G} and D Tilki and P Nuhn and T H{\"o}fner and M Hohenfellner and A Haferkamp and J Roigas and M Zacharias and Wieland, {W F} and H Riedmiller and S Denzinger and Bastian, {P J} and M Burger",
year = "2014",
month = apr,
doi = "10.1007/s00345-013-1105-4",
language = "English",
volume = "32",
pages = "365--71",
journal = "WORLD J UROL",
issn = "0724-4983",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - Clinical and pathological nodal staging score for urothelial carcinoma of the bladder

T2 - an external validation

AU - Gierth, M

AU - Fritsche, H M

AU - Buchner, H

AU - May, M

AU - Aziz, A

AU - Otto, W

AU - Bolenz, C

AU - Trojan, L

AU - Hermann, E

AU - Tiemann, A

AU - Müller, S C

AU - Ellinger, J

AU - Brookman-May, S

AU - Stief, C G

AU - Tilki, D

AU - Nuhn, P

AU - Höfner, T

AU - Hohenfellner, M

AU - Haferkamp, A

AU - Roigas, J

AU - Zacharias, M

AU - Wieland, W F

AU - Riedmiller, H

AU - Denzinger, S

AU - Bastian, P J

AU - Burger, M

PY - 2014/4

Y1 - 2014/4

N2 - PURPOSE: Radical cystectomy (RC) and pelvic lymph node dissection (LND) are standard treatments for muscle-invasive urothelial carcinoma of the bladder. Lymph node staging is a prerequisite for clinical decision-making regarding adjuvant chemotherapy and follow-up regimens. Recently, the clinical and pathological nodal staging scores (cNSS and pNSS) were developed. Prior to RC, cNSS determines the minimum number of lymph nodes required to be dissected; pNSS quantifies the accuracy of negative nodal staging based on pT stage and dissected LNs. cNSS and pNSS have not been externally validated, and their relevance for prediction of cancer-specific mortality (CSM) has not been assessed.METHODS: In this retrospective study of 2,483 RC patients from eight German centers, we externally validated cNSS and pNSS and determined their prediction of CSM. All patients underwent RC and LND. Median follow-up was 44 months. cNSS and pNSS sensitivities were evaluated using the original beta-binominal models. Adjusted proportional hazards models were calculated for pN0 patients to assess the predictive value of cNSS and pNSS for CSM.RESULTS: cNSS and pNSS both pass external validation. Adjusted for other clinical parameters, cNSS can predict outcome after RC. pNSS has no independent impact on prediction of CSM. The retrospective design is the major limitation of the study.CONCLUSIONS: In the present external validation, we confirm the validity of both cNSS and pNSS. cNSS is an independent predictor of CSM, thus rendering it useful as a tool for planning the extent of LND.

AB - PURPOSE: Radical cystectomy (RC) and pelvic lymph node dissection (LND) are standard treatments for muscle-invasive urothelial carcinoma of the bladder. Lymph node staging is a prerequisite for clinical decision-making regarding adjuvant chemotherapy and follow-up regimens. Recently, the clinical and pathological nodal staging scores (cNSS and pNSS) were developed. Prior to RC, cNSS determines the minimum number of lymph nodes required to be dissected; pNSS quantifies the accuracy of negative nodal staging based on pT stage and dissected LNs. cNSS and pNSS have not been externally validated, and their relevance for prediction of cancer-specific mortality (CSM) has not been assessed.METHODS: In this retrospective study of 2,483 RC patients from eight German centers, we externally validated cNSS and pNSS and determined their prediction of CSM. All patients underwent RC and LND. Median follow-up was 44 months. cNSS and pNSS sensitivities were evaluated using the original beta-binominal models. Adjusted proportional hazards models were calculated for pN0 patients to assess the predictive value of cNSS and pNSS for CSM.RESULTS: cNSS and pNSS both pass external validation. Adjusted for other clinical parameters, cNSS can predict outcome after RC. pNSS has no independent impact on prediction of CSM. The retrospective design is the major limitation of the study.CONCLUSIONS: In the present external validation, we confirm the validity of both cNSS and pNSS. cNSS is an independent predictor of CSM, thus rendering it useful as a tool for planning the extent of LND.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Transitional Cell

KW - Chemotherapy, Adjuvant

KW - Cohort Studies

KW - Cystectomy

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Lymph Node Excision

KW - Lymph Nodes

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Pelvis

KW - Proportional Hazards Models

KW - Retrospective Studies

KW - Treatment Outcome

KW - Urinary Bladder Neoplasms

KW - Journal Article

KW - Validation Studies

U2 - 10.1007/s00345-013-1105-4

DO - 10.1007/s00345-013-1105-4

M3 - SCORING: Journal article

C2 - 23736527

VL - 32

SP - 365

EP - 371

JO - WORLD J UROL

JF - WORLD J UROL

SN - 0724-4983

IS - 2

ER -